Verastem VS-7375 胰腺癌/KRAS G12D 数据强劲（2L 确认 ORR 50%），但同步 2.5 亿美元增发大幅摊薄并换帅

Verastem Oncology, Inc. (VSTM), a biopharmaceutical company focused on cancer treatments, reported clinical data showing responses to its investigational KRAS G12D inhibitor VS-7375 across pancreatic, non-small cell lung and colorectal cancers. The company also announced a $250 million public offering and a leadership transition, with Michael P. Bailey set to become President and CEO in January 2027.
KRAS G12D-Mutated Cancers
KRAS G12D is a cancer-associated mutation that drives tumor growth and is found in several solid tumors, including pancreatic, colorectal and lung cancers. Treatment options targeting this mutation remain limited, creating a need for therapies that directly inhibit its activity.
VS-7375 is an investigational oral KRAS G12D ON/OFF inhibitor designed to target cancer cells carrying the mutation. Verastem is evaluating the candidate across multiple solid tumor types in its Phase 1/2 TARGET-D 101 clinical trial.
Phase 1/2 TARGET-D 101 Trial Results
In second-line-or-later pancreatic ductal adenocarcinoma (PDAC), VS-7375 at 900 mg once daily achieved an objective response rate (ORR) of 41% among 22 patients, including two complete responses, one confirmed and one unconfirmed. The disease control rate was 86%, while six-month landmark progression-free survival and overall survival rates were 67% and 80%, respectively.
In non-small cell lung cancer, the 600 mg once-daily dose achieved a confirmed ORR of 43% among 23 patients treated in the second-line-or-later setting. In colorectal cancer, VS-7375 combined with an anti-EGFR therapy produced an ORR of 33% among six patients, including one confirmed and one unconfirmed response.
Verastem also reported complete circulating tumor DNA clearance by cycle 3, day 1, in seven of 12 evaluable PDAC patients. At the 900 mg dose, adverse events led to treatment discontinuation in 2% of patients, with gastrointestinal effects primarily low grade.
Verastem's Phase 3 Development Plans
Following discussions with the U.S. Food and Drug Administration, Verastem plans to initiate a Phase 3 trial of VS-7375 in first-line metastatic pancreatic cancer by the end of 2026. The proposed study will evaluate VS-7375 in combination with an anti-EGFR therapy or gemcitabine/nab-paclitaxel against standard chemotherapy.
The company expects to report additional clinical data and Phase 2 study results through 2027 as it advances the candidate's development.
Verastem's $250 Million Public Offering
Separately, Verastem priced an underwritten public offering of 30,937,500 common shares at $8.00 per share and pre-funded warrants to purchase 312,503 shares at $7.9999 each. The offering is expected to generate approximately $250 million in gross proceeds before underwriting discounts and expenses.
The company intends to use the proceeds to support VS-7375 clinical development, working capital and general corporate purposes. The offering is expected to close on October 15, 2026, subject to customary closing conditions.
Verastem's Leadership Transition
Verastem announced that Michael P. Bailey will become President and CEO effective January 1, 2027, succeeding Daniel Paterson, who plans to retire from the position after a 35-year biotechnology career. Paterson will continue as an advisor and board member.
Bailey brings more than 30 years of biopharmaceutical experience, including oncology leadership and service as CEO of AVEO Oncology. He has served on Verastem's board since May 2026.
VSTM has traded in a 52-week range of $3.43 to $10.82.
The stock closed Tuesday's trading at $7.45, down 9.70%.
In the premarket trading, shares are up 19.31% at $8.94.
For comments and feedback contact: editorial@rttnews.com
Business News
October 09, 2026 15:35 ET The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.